ArticleFrontiers in oncology2026
Beneficial effect of adjuvant traditional Chinese medicine therapy on body constitution symptoms and quality of life among breast cancer patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer therapies effectively control tumors but frequently impose substantial symptom burden and impair quality of life (QOL). In integrative oncology practice, traditional Chinese medicine (TCM) is commonly used as adjunctive supportive care. We evaluated associations between adjunctive scientific Chinese herbal medicine (CHM), constitution-related symptoms, and QOL in a real-world breast cancer cohort. Methods: In this prospective observational study, 83 patients receiving Western medicine (WM) were followed for 3-6 months and categorized as WM alone or WM plus adjunctive CHM. Baseline imbalance was addressed using inverse probability of treatment weighting (IPTW), and repeated measures were analyzed using generalized estimating equation (GEE) models to estimate associations between CHM exposure and improvements in BCQ and WHOQOL-BREF outcomes. Results: After IPTW adjustment, adjunctive CHM use was associated with higher odds of improvement in BCQ symptoms including fatigue (OR 1.92, 95% CI 1.18-3.12), dry eyes (OR 2.15, 95% CI 1.27-3.65), and hot flushes (OR 1.87, 95% CI 1.10-3.19), compared with WM alone. Associations were also observed in WHOQOL-BREF, including reduced interference from physical pain (OR 2.08, 95% CI 1.24-3.50) and improved perception of physical environment (OR 1.69, 95% CI 1.03-2.76). These symptom patterns are consistent with traditional Chinese medicine descriptions commonly characterized as qi-yin deficiency with stasis-stagnation. Conclusion: In this real-world integrative oncology setting, adjunctive scientific CHM use was associated with improvements in constitution-related symptoms and selected QOL domains. These findings suggest a potential supportive role for CHM in breast cancer care; however, causal inference cannot be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.